0000000000365729

AUTHOR

Arife ÖZveren

showing 2 related works from this author

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure : the DIANA study

2020

© 2020 The Author(s).

OriginalDELPHI METHODCritical Care and Intensive Care MedicineGUIDELINESlaw.invention0302 clinical medicineAnti-Infective Agents[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawEpidemiologyMedicine and Health SciencesAntimicrobial de-escalationEPIDEMIOLOGYComputingMilieux_MISCELLANEOUS[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesVentilator-associated pneumoniaIntensive care unitAnti-Bacterial Agents3. Good healthIntensive Care UnitsSTEWARDSHIP PROGRAM[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohortAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unit;Clinical cureAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unitAdultmedicine.medical_specialtyCombination therapyCritical IllnessANTIBIOTIC-THERAPYNO03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBETA-LACTAMInternal medicineSettore MED/41 - ANESTESIOLOGIAmedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care unitVENTILATOR-ASSOCIATED PNEUMONIAbusiness.industrySEPTIC SHOCKR-PACKAGEbacterial infectionIntensive care unit.030208 emergency & critical care medicinemedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEmpirical therapyDiscontinuationSEVERE SEPSISlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Carbapenems030228 respiratory systemRelative riskBacterial infectionbusinessDe-escalation
researchProduct